Edition:
United Kingdom

Melinta Therapeutics, Inc. (MLNT.OQ)

MLNT.OQ on NASDAQ Stock Exchange Global Select Market

13.10USD
3:12pm GMT
Change (% chg)

$0.25 (+1.95%)
Prev Close
$12.85
Open
$12.95
Day's High
$13.20
Day's Low
$12.85
Volume
5,873
Avg. Vol
43,132
52-wk High
$24.25
52-wk Low
$10.50

Chart for

About

Melinta Therapeutics, Inc. develops and commercializes novel antibiotics designed to provide therapeutic solutions. The Company’s lead product is Baxdela, an antibiotic approved by the United States food and drug administration (FDA) for use in the treatment of acute bacterial skin and skin structure infections (ABSSSI). The... (more)

Overall

Beta: 1.07
Market Cap(Mil.): $166.71
Shares Outstanding(Mil.): 52.51
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Melinta Therapeutics Launches Antibiotic Baxdela In U.S.

* MELINTA THERAPEUTICS LAUNCHES ANTIBIOTIC BAXDELA™ (DELAFLOXACIN) IN THE UNITED STATES Source text for Eikon: Further company coverage:

29 Jan 2018

BRIEF-Melinta Therapeutics Files For Mixed Shelf Offering Of Upto $150 Million

* MELINTA THERAPEUTICS INC FILES FOR MIXED SHELF OFFERING OF UPTO $150 MILLION - SEC FILING Source text - http://bit.ly/2DSYZpm Further company coverage:

26 Jan 2018

BRIEF-Melinta Therapeutics Says ‍Partner Commenced New Program For Topical Formulation Of Radezolid, In Preparation For Submitting IND Application To FDA

* MELINTA THERAPEUTICS - ‍PARTNER COMMENCED NEW PROGRAM FOR A TOPICAL FORMULATION OF RADEZOLID, IN PREPARATION FOR SUBMITTING AN IND APPLICATION TO FDA Source text for Eikon: Further company coverage:

18 Jan 2018

BRIEF-Melinta Therapeutics Files For Resale Of Up To 6.9 Mln Shares By Selling Stockholders

* MELINTA THERAPEUTICS INC FILES FOR RESALE OF UP TO 6.9 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING‍​ Source text: (http://bit.ly/2EqugN6) Further company coverage:

09 Jan 2018

BRIEF-Melinta Therapeutics Files For Resale Of Up To 3.3 Mln Shares By Selling Stockholder

* MELINTA THERAPEUTICS INC FILES FOR RESALE OF UP TO 3.3 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDER - SEC FILING Source text for Eikon: (http://bit.ly/2CO48LP) Further company coverage:

09 Jan 2018

BRIEF-Deerfield Management Reports 10 Pct Passive Stake In Melinta Therapeutics

* DEERFIELD MANAGEMENT COMPANY LP REPORTS A 10 PCT PASSIVE STAKE IN MELINTA THERAPEUTICS INC AS OF JAN 5 - SEC FILING Source text for Eikon: (http://bit.ly/2Eqi9zA) Further company coverage:

09 Jan 2018

BRIEF-Medicines Company Announces Definitive Agreement To Sell Its Infectious Disease Business Unit To Melinta Therapeutics

* THE MEDICINES COMPANY ANNOUNCES DEFINITIVE AGREEMENT TO SELL ITS INFECTIOUS DISEASE BUSINESS UNIT TO MELINTA THERAPEUTICS

29 Nov 2017

BRIEF-Melinta Therapeutics Enters Agreement To Acquire Infectious Disease Business From The Medicines Company

* MELINTA THERAPEUTICS ENTERS INTO AGREEMENT TO ACQUIRE INFECTIOUS DISEASE BUSINESS FROM THE MEDICINES COMPANY Source text for Eikon: Further company coverage:

29 Nov 2017

Competitors

  Price Chg
Astellas Pharma Inc (4503.T) ¥1,509 +0.50
Johnson & Johnson (JNJ.N) $130.21 +0.30
Pfizer Inc. (PFE.N) $35.83 +0.07
Roche Holding Ltd. (ROG.S) CHF221.25 -2.25
Roche Holding Ltd. (RO.S) CHF225.20 -2.40
Abbott Laboratories (ABT.N) $59.03 +0.04
Bayer AG (BAYGn.DE) €97.59 -0.84
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €64.48 -0.22
AstraZeneca plc (AZN.L) 4,777.50 -22.00

Earnings vs. Estimates